A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than plasma levels achieved by clinically effective dosing, the anti-CTLA-4 antibody Ipilimumab blocks neither B7 trans-endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xuexiang, Tang, Fei, Liu, Mingyue, Su, Juanjuan, Zhang, Yan, Wu, Wei, Devenport, Martin, Lazarski, Christopher A, Zhang, Peng, Wang, Xu, Ye, Peiying, Wang, Changyu, Hwang, Eugene, Zhu, Tinghui, Xu, Ting, Zheng, Pan, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939050/
https://www.ncbi.nlm.nih.gov/pubmed/29472691
http://dx.doi.org/10.1038/s41422-018-0011-0

Ejemplares similares

Ejemplares similares